Tendon & Ligament
BPC-157 is studied in tendon models while TB-500 is characterised for cell migration toward the injury site; the pairing is investigated as a combined condition.
≥99% Purity
BPC-157 / TB-500
Two-peptide blend · 20 mg lyophilized
$100.00$50.00/vial with BOGO
USA Lab VerifiedISO/IEC 17025:2017
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
This is a blend. BPC-157 and TB-500 are combined in a single 20 mg vial. Both appear in tissue remodelling research, but they work through different routes. BPC-157 has been studied at growth factor pathways, while TB-500 has been studied at actin, a protein that gives cells their shape and allows them to move. Researchers use blends to compare combined conditions against single compounds.
Dual-peptide blend: BPC-157 (15-aa pentadecapeptide) + TB-500 (43-aa active fragment of Thymosin Beta-4)
- Form
- Lyophilized powder blend
- Purity
- ≥99% per component (HPLC verified)
- Vial size
- 20mg
- Class
- Peptide blend
0
Synergistic Pathways
VEGF + Actin regulation
0+
Combined Studies
BPC-157 (200+) + TB-500 (170+)
0%
Dual Pathway Coverage
TB-500 re-epithelialization
0
Research Areas
Tendon & Ligament · Wound Closure · Vascular Models & more
How It Works
How BPC-157 / TB-500 works
The pathways BPC-157 / TB-500 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Angiogenesis & Cytoprotection
BPC-157
Raised VEGF expression and new vessel formation have been measured for BPC-157, alongside perfusion of the surrounding tissue. NO system activity and cytoprotective endpoints are also characterised.
- VEGF-mediated angiogenesis
- Nitric oxide system modulation
- Gastric and tissue cytoprotection
Cell Migration & Actin Regulation
TB-500
TB-500 sequesters G-actin monomers, with cytoskeletal remodelling and cell migration toward injury sites measured. Integrin-linked kinase (ILK) signalling is also characterised.
- Actin-mediated cell migration
- Integrin-linked kinase activation
- Anti-fibrotic remodeling
Complementary Pathways
Synergy
BPC-157 is characterised on vascular endpoints (perfusion at the injury site), TB-500 on cell mobilisation to the same site. The two cover distinct pathways — perfusion and cellular migration.
- Perfusion endpoints (BPC-157)
- Phase 2: Cell mobilization (TB-500)
- Combined anti-inflammatory effects
Uses & Applications
What BPC-157 / TB-500 is researched for
The main areas BPC-157 / TB-500 is being studied for — and the study-reported figures behind them.
Wound Closure Models
TB-500 is studied in dermal and scarring models; BPC-157 for vascular endpoints including perfusion at wound sites.
Vascular Models
Angiogenesis via the NO system is measured for BPC-157; cardiac cell migration through ILK activation for TB-500.
Inflammatory Signalling
Anti-inflammatory endpoints are measured for both peptides through distinct mechanisms.
Molecular Structure
The BPC-157 / TB-500 molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
Molecular model
Compound Information
Full specification
| Components | BPC-157 + TB-500 (Thymosin Beta-4) |
| BPC-157 Sequence | 15 amino acids (Gly-Glu-Pro-Pro-Pro...) |
| TB-500 Fragment | 43-amino acid active region of Tβ4 |
| Form | Lyophilized powder blend |
| Purity | ≥99% per component (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
| Strength | 20mg |
| Purity (HPLC) | >99% (HPLC) |
| Appearance | White to off-white powder |
| Stability | 24 months from manufacture date when stored properly |
FAQ
Common questions about BPC-157 / TB-500
BPC-157 and TB-500 act through complementary mechanisms. Vessel formation (angiogenesis) and perfusion are measured for BPC-157; cell mobilisation via actin regulation for TB-500. The pairing covers vascular and cellular-migration pathways.
No. The combination has not been characterised as a single formulation. The rationale is based on complementary mechanisms described for each component individually in preclinical models.
No. Neither BPC-157 nor TB-500 is FDA approved for any indication. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human consumption.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles. Both components maintain stability under standard peptide storage conditions.
Each component undergoes independent third-party testing including HPLC for purity verification, mass spectrometry for molecular weight confirmation, and endotoxin testing. A Certificate of Analysis is included with every order.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.